Impact of Non-Alcoholic Fatty Liver Disease on Sepsis Inpatient Outcomes: A Nationwide Sample Analysis (2000–2019)
Open Access
- 26 September 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (19) , 5737
Abstract
Background/Objectives: Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) are reported to have an increased risk of developing severe infections, leading to hospitalizations with sepsis. However, data regarding the impact of comorbid NAFLD on in-hospital outcomes of patients with sepsis is scarce. Methods: This nationwide retrospective observational study using discharge data from the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), and Agency for Healthcare Research and Quality included 21,057,911 adult patients who were admitted to hospitals in the United States between 2000 and 2019 with a primary discharge diagnosis of sepsis. These patients were categorized according to the presence or absence of comorbid NAFLD. The twenty-year trend of nationwide NAFLD prevalence among sepsis inpatients was elucidated. Multivariable logistic regression analysis was used to analyze NAFLD’s impact on sepsis outcomes. Results: In the twenty-year study period, the prevalence of NALFD among sepsis inpatients trended up from 1.2% in 2000 to 4.2% in 2019. Similar trends were observed in regional analysis. While overall sepsis mortality decreased, comorbid NAFLD in sepsis patients was consistently associated with a higher adjusted in-hospital all-cause mortality rate (adjusted odds ratio (OR), 1.19; 95% confidence interval (CI), 1.07–1.32), higher odds of developing septic shock, and higher likelihood of development of multi–organ dysfunction. Conclusions: Comorbid NAFLD in the stage of NASH or cirrhosis is associated with higher in-hospital all-cause mortality and worse clinical outcomes in sepsis inpatients. Addressing this rising epidemic will be of paramount importance to improve sepsis in-hospital outcomes.Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease – A Population-based Cohort StudyClinical Gastroenterology and Hepatology, 2023
- Geographic Variation in NAFLD Prevalence and Subspecialty Care Utilization Among Insured Adults in the United StatesClinical Gastroenterology and Hepatology, 2023
- Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection FractionCurrent Problems in Cardiology, 2022
- NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort studyInternal and Emergency Medicine, 2022
- Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19JAMA Network Open, 2021
- A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational StudiesJAMA, 2021
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver DiseaseArchives of Medical Research, 2021
- Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver DiseaseHepatology Communications, 2020
- Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care HospitalsJAMA Network Open, 2019
- Adherence to Methodological Standards in Research Using the National Inpatient SampleJAMA, 2017